Brief: Ampion Reduces All-Cause Mortality In Covid-19 Respiratory Distress By Nearly 80%

Ampio Pharmaceuticals

27/04/2021 14:43

April 27 (Reuters) - Ampio Pharmaceuticals Inc  AMPE.A :
    * AMPION™ REDUCES ALL-CAUSE MORTALITY IN COVID-19
RESPIRATORY
DISTRESS BY NEARLY 80%
    * AMPIO PHARMACEUTICALS INC - ALL-CAUSE MORTALITY IN
PATIENTS
TREATED USING STANDARD OF CARE (SOC) WAS 24%, BUT ONLY 5% IN
GROUP TREATED WITH AMPION
    * AMPIO PHARMACEUTICALS INC - AP-014 PHASE I TRIAL OF
INHALED
AMPION IN COVID-19 RESPIRATORY DISTRESS MEETS PRIMARY ENDPOINT
    * AMPIO PHARMACEUTICALS INC - PHASE II TRIALS UTILIZING
INHALED
AND INTRAVENOUS AMPION READY TO ENROLL PATIENTS
    * AMPIO PHARMACEUTICALS INC - AMPION TREATMENT WAS SAFE AND
WELL-TOLERATED IN ALL PATIENTS
    * AMPIO PHARMACEUTICALS INC - THERE WERE NO REMARKABLE
ADVERSE
EVENTS WITH AMPION TREATMENT, AND NO DRUG-RELATED SERIOUS
ADVERSE EVENTS WERE REPORTED

Source text for Eikon:  ID:nPn63RjnBa 
Further company coverage:  AMPE.A 

 ((Reuters.Briefs@thomsonreuters.com;))